VEGFR-3/FLT4 Protein, Human (Biotinylated, HEK293, His-Avi)

VEGFR-2 protein is an important tyrosine protein kinase receptor that serves as a cell surface receptor for VEGFA, VEGFC and VEGFD to regulate angiogenesis, blood vessel development and embryonic hematopoiesis. It enhances endothelial cell proliferation, survival, migration and differentiation. VEGFR-3/FLT4 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived VEGFR-3/FLT4 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

VEGFR-2 protein is a tyrosine-protein kinase receptor that plays a crucial role in regulating various processes including angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. It acts as a cell-surface receptor for VEGFA, VEGFC, and VEGFD, promoting the proliferation, survival, migration, and differentiation of endothelial cells. Additionally, isoforms lacking a transmembrane domain, such as isoform 2, act as decoy receptors for VEGFA, VEGFC, and/or VEGFD, serving as negative regulators of lymphangiogenesis by inhibiting the binding of these growth factors to FLT4. VEGFR-2 also forms heterodimers with FLT1 and FLT4, modulating their signaling. Activation of isoform 1 by vascular growth factors triggers multiple signaling cascades, including the activation of PLCG1, resulting in the production of diacylglycerol and inositol 1,4,5-trisphosphate, as well as the activation of protein kinase C. It also activates MAPK1/ERK2, MAPK3/ERK1, and AKT1 signaling pathways, leading to various cellular responses. Moreover, VEGFR-2 phosphorylates PIK3R1, facilitating the activation of phosphatidylinositol 3-kinase, and promotes actin cytoskeleton reorganization and activation of PTK2/FAK1. Its role in NOS2 and NOS3 induction leads to the production of nitric oxide (NO) by endothelial cells. Additionally, VEGFR-2 phosphorylates PLCG1 and promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1, and SRC, further contributing to its diverse cellular functions.

1.This product does not contain protein kinase domain.
2.Immobilized Human VEGF-C, His Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Biotinylated Human VEGF R3, His Tag with the EC₅₀ of 24.3ng/ml determined by ELISA.

Human

HEK293

C-Avi;C-His

P35916-1 (Y25-I776)

2324  [NCBI]

Partial

Biotin

YSMTPPTLNITEESHVIDTGDSLSISCRGQHPLEWAWPGAQEAPATGDKDSEDTGVVRDCEGTDARPYCKVLLLHEVHANDTGSYVCYYKYIKARIEGTTAASSYVFVRDFEQPFINKPDTLLVNRKDAMWVPCLVSIPGLNVTLRSQSSVLWPDGQEVVWDDRRGMLVSTPLLHDALYLQCETTWGDQDFLSNPFLVHITGNELYDIQLLPRKSLELLVGEKLVLNCTVWAEFNSGVTFDWDYPGKQAERGKWVPERRSQQTHTELSSILTIHNVSQHDLGSYVCKANNGIQRFRESTEVIVHENPFISVEWLKGPILEATAGDELVKLPVKLAAYPPPEFQWYKDGKALSGRHSPHALVLKEVTEASTGTYTLALWNSAAGLRRNISLELVVNVPPQIHEKEASSPSIYSRHSRQALTCTAYGVPLPLSIQWHWRPWTPCKMFAQRSLRRRQQQDLMPQCRDWRAVTTQDAVNPIESLDTWTEFVEGKNKTVSKLVIQNANVSAMYKCVVSNKVGQDERLIYFYVTTIPDGFTIESKPSEELLEGQPVLLSCQADSYKYEHLRWYRLNLSTLHDAHGNPLLLDCKNVHLFATPLAASLEEVAPGARHATLSLSIPRVAPEHEGHYVCEVQDRRSHDKHCHKKYLSVQALEAPRLTQNLTDLLVNVSDSLEMQCLVAGAHAPSIVWYKDERLLEEKSGVDLADSNQKLSIQRVREEDAGRYLCSVCNAKGCVNSSASVAVEGSEDKGSMEI

Approximately 115-130 kDa,based on SDS-PAGE under reducing conditions,due to the glycosylation.

≥ 95%, as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. Normally 8% trehalose is added as protectant before lyophilization.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.